Markets

Belgian biotech Galapagos files for a $150 million US IPO

A generic image of a dollar in front of a graph
Credit: Shutterstock photo

Galapagos, a Belgian biotech developing new treatments for inflammatory diseases, filed on Wednesday with the SEC to raise up to $150 million in an initial public offering. Galapagos currently trades on the Euronext under the symbol GLPG. It closed at €29.00 on Wednesday, giving the company a market cap of €895 million.

The Mechelen, Belgium-based company, which was founded in 1999 and booked €90 million in sales for the 12 months ended December 31, 2014, plans to list on the NASDAQ under the symbol GLPG. Galapagos initially filed confidentially on 2/6/2015. Morgan Stanley, Credit Suisse and Cowen & Company are the joint bookrunners on the deal.

The article Belgian biotech Galapagos files for a $150 million US IPO originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.

Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital, the Renaissance IPO ETF (symbol: IPO) or the Global IPO Fund (symbol: IPOSX) , may have investments in securities of companies mentioned.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Other Topics

IPOs

Latest Markets Videos

    Renaissance Capital

    Renaissance Capital is the global leader in providing pre-IPO institutional research and management of IPO-focused investment products.

    Learn More